Web5 nov. 2024 · One pt had an autologous stem cell transplant and 1 pt had an allogeneic stem cell transplant as part of frontline treatment. Fifty-one (76%) pts had a complete … Web3 jan. 2024 · Selinexor. In 2024, selinexor was approved by the FDA for use in adult patients with R/R DLBCL (including follicular lymphoma-derived DLBCL) after at least 2 lines of …
New Treatment Options for Relapsed or Refractory …
WebIn this case report, we describe the successful treatment of DLBCL which originally presented as ALF through bridging therapy with a non-standard bendamustine-based … Web14 apr. 2024 · ASH 2024- Emergence of Bispecific antibodies in DLBCL: Prospects, Opportunities, and Challenges The American Society of Hematology (ASH) Annual Meeting this year presented abstracts showcasing new data from across its bispecific antibodies clinical pipeline, demonstrating the companies’ commitment to redefining care for … fitness factory london ontario
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and ...
Web3 aug. 2024 · By using an immunohistochemical approach to assess MYC protein expression in formalin-fixed, paraffin-embedded tissue, a group from Denmark evaluated … Web5 dec. 2024 · SAN DIEGO—A shortened regimen of four cycles of rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy was noninferior in efficacy to the standard six cycles of R-CHOP in younger patients with favorable-risk diffuse large B-cell lymphoma (DLBCL), according Web25 nov. 2024 · Second-line treatment for relapsed or refractory DLBCL is based on stratification for transplant eligibility/ineligibility. Transplant-eligible patients are treated … can i borrow a puppy